14th ICID - Poster Abstracts - International Society for Infectious ...

More documents

Recommendations

Info

When citing these abstracts please use the following reference: Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number. Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1 is available electronically on http://www.sciencedirect.com Final Abstract Number: 83.017 Session: Vaccines and Vaccine Development Date: Thursday, March 11, 2010 Time: 12:30-13:30 Room: Poster & Exhibition Area/Ground Level Type: Poster Presentation Influenza vaccine: Immunization rates, knowledge, attitudes and practice of health care workers in Iran in 2008/09 Z. Khazaeipour 1 , N. ranjbar novin 2 , N. Hoseini 1 1 Health deputy of Tehran University of Medical Science, Tehran, Iran, Islamic Republic of, 2 Research Development Centerof Imam Khomeini Hospital Complex , tehran, Iran, Islamic Republic of Background: Influenza is an important cause of excessive morbidity and mortality each winter. Its short incubation period and efficient transmission from person to person makes influenza hazardous to the patients and staff in healthcare facilities. The aims of this study were to determine influenza vaccine coverage and evaluate the knowledge, attitudes and practice about influenza and vaccine. Methods: This study was a cross-sectional survey that was performed between October 2008 and February 2009 in 139 health care workers (HCWs) of health deputy of Tehran University of medical science, Tehran, Iran. They received a self-administered questionnaire and then the research assistant waited to collect them. Results: The response rate to the questionnaire was 96.5%. The influenza vaccination coverage for the 2008–2009 seasons was 66.9 % (range, 45% to 62%). Most HCWs (80.6%) had received an influenza vaccination in the past, and 65.4% intended to receive vaccination in the future year. The main reason given for being immunized was effectiveness of influenza vaccine (51.4%). The main reason given for not being immunized was concerned about side-effects (23.1%). The knowledge score for the 35 items ranged from 0 to 34 (mean 17.37). Mean knowledge scores differed between courses. There was no significant difference in mean knowledge scores between female and male (P > 0.05) None of independent variables included age, sex, marital status, having children aged 16 years and courses were significant predictors of taking influenza immunization. Conclusion: In our study, despite high coverage rate of influenza vaccination in comparison with other studies, we would expect higher rate because of free vaccine availability. The study results indicate that there is the need for on-going education of Influenza disease, vaccine action and Centers for Disease Control and Prevention (CDC) recommendation among HCWs to increasing vaccination rates.
When citing these abstracts please use the following reference: Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number. Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1 is available electronically on http://www.sciencedirect.com Final Abstract Number: 83.018 Session: Vaccines and Vaccine Development Date: Thursday, March 11, 2010 Time: 12:30-13:30 Room: Poster & Exhibition Area/Ground Level Type: Poster Presentation Variable serological response to PPV in HIV-positive patients – A need to review pneumococcal boost-prime strategies? A. Brown 1 , C. Rock 2 , C. Ní Bhuachalla 1 , T. Coulter 1 , C. Dowling 1 , C. Bergin 1 1 St. James's Hospital, Dublin, Ireland, 2 Cork University Hospital, Dublin, Ireland Background: International guidelines recommend 23-polyvalent polysaccharide pneumococcal vaccination (PPV) for HIV-positive patients with CD4 >200 cells/mm3. Historical data shows suboptimal response to vaccination in HIV-positive patients when measured by pneumococcalspecific IgG and vaccine serotype-specific IgG2. There is little data to support the efficacy of vaccination in consistently producing serological response, or assessing the role of conjugate vaccine in adults. Methods: In a cross-sectional study, 82 random samples were taken from HIV-positive outpatients. The samples were assessed for pneumococcal IgG and IgG2. IgG2 levels >69μg/L are considered good serological evidence of response in the absence of baseline titres with which to compare post-vaccination response. Demographic, vaccination and laboratory data was recorded. Results were analysed using Fisher’s exact test and two-tailed p values with GraphPad InStat. Results: Four patients were excluded with no prior history of pneumococcal vaccination, and two for incomplete data. The remaining 76 patients(M= 47, F= 29) were aged between 21 and 71 years (mean= 39.1yrs, SD 9.86) at the time of first vaccination. Twenty-six patients (34%) received booster. Sixty-one patients (80%) were taking ART at the time of sampling. Thirteen patients (17.1%) had vaccine serotype-specific IgG2 titre 69μg/L at the time of sampling. Achieving an IgG2 titre 69μg/L was not associated with any of the measured variables — age < vs 35 yrs at vaccination(p=0.54); male vs female sex(p=0.54); CD4 count
Page 1 and 2:
When citing these abstracts please
Page 3 and 4:
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206: When citing these abstracts please
Page 255: When citing these abstracts please
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
show all

14th ICID - Poster Abstracts - International Society for Infectious ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?